Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03808883 · ClinicalTrials.gov registry record · NA

TRANSLATE: Transgender and Gender Nonconforming Individuals' Access to Healthcare

A NA study, sponsored by Case Western Reserve University.

Completed
Registry status
NA
Development phase
49
Enrollment target

NCT03808883: Completed NA study, sponsored by Case Western Reserve University.

NCT03808883 is a NA study that has completed, run by Case Western Reserve University. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03808883, a NA study, has completed, sponsored by Case Western Reserve University.

COMPLETED
Registry status
NA
Development phase
49 participants
Enrollment target

Study Summary

Transgender and gender nonconforming (TGNC) individuals face a number of health disparities, many of which can be tied to a lack of access to or use of primary care. Stigma and misunderstanding make simple doctor's visits into ordeals only worth enduring for the most serious of problems. This project addresses those issues by enlisting TGNC people as experts on their own experience. TGNC individuals will form a year-long cohort that will form the basis for this research. Collectively, they will define the scope of challenges faced when seeking healthcare, what medical advocacy training they desire, and how to address groups of healthcare providers and staff. Healthcare providers, including MDs, nurses, and Physicians Assistants (PAs), will attend two facilitated sessions with the TGNC cohort to meet as peers with knowledge exchanged in both directions. Similar meetings will occur with clinic staff, as TGNC individuals have expressed how stigma begins from the moment they call a medical office. Our hypothesis is that when TGNC individuals are given the tools to navigate the healthcare system and the ability to speak with medical professionals as peers, rather than patients, through a participatory action research design they will be better able to access appropriate care through increased confidence and mutual support. The complementary hypothesis for medical providers is that direct interaction with a variety of TGNC individuals who articulate their needs will decrease stigma and increase comfort when treating TGNC people as patients. As a partnership between academic, medical, and community institutions, this project has the potential to directly impact the lives of TGNC individuals who participate and indirectly impact others served by the LGBT Center. This proposal works on three levels: 1) at the academic level - an assessment of participatory action research as an intervention to decrease health disparities, 2) at the individual level - the potential for indivi

Primary Outcome

TGNC participants were asked pre and post-intervention to name all the hospitals they knew of where they could received medical care. Mean and range are reported. This measure was unreliable as participants, when asked in the post survey to name locations for healthcare, were not given those they had identified in the pre-intervention survey, so some participants actually decreased the number they named. Additionally, growth from this measure is mean growth of the group, not a mean of the sum of

Interventions

  • BEHAVIORAL TGNC Directed Advocacy Meetings
  • BEHAVIORAL Facilitated Dialogues between TGNC Cohort and Healthcare Participants

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2019-02-01
Est. Completion 2020-12-10
Phase NA
Case Western Reserve University

141 total trials

What the finished NCT03808883 record still lists

NCT03808883 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which TGNC Directed Advocacy Meetings is the first listed.

NCT03808883 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03808883 about?

NCT03808883 is a clinical study titled "TRANSLATE: Transgender and Gender Nonconforming Individuals' Access to Healthcare". Transgender and gender nonconforming (TGNC) individuals face a number of health disparities, many of which can be tied to a lack of access to or use of primary care. Stigma and misunderstanding make simple doctor's visits into ordeals only worth enduring for the most serious of problems. This projec...

What is the current status of trial NCT03808883?

This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2019-02-01. Estimated completion is 2020-12-10.

What interventions are being tested in trial NCT03808883?

The interventions under investigation include: TGNC Directed Advocacy Meetings (BEHAVIORAL), Facilitated Dialogues between TGNC Cohort and Healthcare Participants (BEHAVIORAL).

Who is sponsoring clinical trial NCT03808883?

This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03808883's enrollment target sits among peer trials

49 1379th of 2000 higher than 620 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02704858 · 49 participants · Phase 1

    Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

  • NCT03516708 · 49 participants · Phase 1

    Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

  • NCT03692429 · 49 participants · Phase 1

    alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

  • NCT04329494 · 49 participants · Phase 1

    PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03808883, the US trial registry maintained by the National Library of Medicine. NCT03808883 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.